Reverse Merger Injects Capital Into New Migraine Target: Slate Raises $245 Million to Advance PACAP/VIP Antibody

Migraine prevention has already been reshaped by CGRP antibodies, but not all patients achieve adequate improvement. Fulcrum Therapeutics and Slate Medicines are now betting on another neuropeptide pathway through an all-stock merger and a $245 million private placement, seeking to advance a dual-target antibody that has not yet generated human data to the proof-of-concept stage.

The transaction is effectively a reverse merger: private company Slate will enter the public market through Nasdaq-listed Fulcrum. The combined company will retain the Slate Medicines name and is expected to trade under the ticker “SLTE.” The transaction remains subject to approval by shareholders of both companies and is targeted for completion in the fourth quarter of 2026; the private placement is also expected to close concurrently with the merger.

The new company’s lead asset, SLTE-1009, is a monoclonal antibody that binds PACAP-38, PACAP-27, and vasoactive intestinal peptide, or VIP. PACAP is associated with migraine attacks and acts through a pathway that is not entirely the same as the currently predominant CGRP target. Slate argues that blocking PACAP and VIP simultaneously may provide broader coverage than inhibiting PACAP alone, but this differentiation thesis is currently based mainly on preclinical data.

SLTE-1009 has also been designed for an extended half-life, with development targeting subcutaneous administration and a dosing interval of up to once quarterly. Fewer injections or the elimination of intravenous infusions could indeed reduce the burden of long-term preventive treatment; however, the actual half-life, appropriate dose, and dosing frequency must all be confirmed through human pharmacokinetic and safety data.

In July 2026, Slate received approval from an Australian Human Research Ethics Committee for a Phase 1 trial, which will initially evaluate safety and pharmacokinetics in healthy volunteers. The company expects to obtain preliminary pharmacokinetic and half-life data in mid-2027, report more complete Phase 1 results in the second half of 2027, and initiate a Phase 2 dose-ranging trial in patients with migraine. This means that although the financing could support key clinical milestones, actual evidence of efficacy remains at least one Phase 1 trial away.

The competitive landscape is also challenging. A PACAP antibody has previously suffered a setback in a mid-stage trial, while Lundbeck’s bocunebart has reported positive Phase 2 results. New long-acting PACAP antibodies and bispecific PACAP/CGRP antibodies are also entering development. Whether Slate can establish an advantage through the additional blockade of VIP and less frequent dosing can only be assessed once directly comparable clinical endpoints and tolerability data become available.

Slate also has SLTE-2100, a bispecific antibody designed to target PACAP/VIP and CGRP simultaneously, which is expected to enter a Phase 1 trial in the second half of 2027. Before this merger, Fulcrum had discontinued development of the sickle cell disease candidate pociredir and begun exploring strategic options because of regulators’ concerns about a potential carcinogenic risk associated with drugs in the same class. The transaction is therefore both a route for Slate to secure capital and a public listing platform and a complete pivot for Fulcrum following the termination of its previous research and development focus.